NCT00127192View on ClinicalTrials.gov

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

PHASE2CompletedINTERVENTIONAL
Enrollment

363

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

sitagliptin phosphate

sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.

DRUG

Comparator: placebo (unspecified)

placebo QD 12-weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00127192 - A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044) | Biotech Hunter | Biotech Hunter